학술논문
47P Phase I study to assess the safety and efficacy of P-BCMA-ALLO1: A fully allogeneic CAR-T therapy, in patients with relapsed/refractory multiple myeloma (RRMM)
Document Type
Abstract
Author
Source
In Immuno-Oncology and Technology December 2022 16 Supplement 1
Subject
Language
ISSN
2590-0188